TSE:4523Pharmaceuticals
How New Long-term Leqembi Data And At-home Injections At Eisai (TSE:4523) Have Changed Its Investment Story
Eisai and Biogen recently presented new long-term data at the CTAD 2025 conference showing that Leqembi (lecanemab) treatment, including a subcutaneous autoinjector formulation, may substantially delay progression from mild cognitive impairment to more advanced Alzheimer’s disease while maintaining a safety profile consistent with earlier trials.
The findings that earlier and continued Leqembi use could translate into several additional years before patients reach moderate Alzheimer’s stage,...